linjc16/ctgov huggingface dataset:
The Incidence and Treatment of Insulin Resistance Among Men With Erectile Dysfunction

Study Overview
=================
Brief Summary
-----------------
Determine if men with erectile dysfunction (ED) are more likely to have insulin resistance compared to healthy controls.

Detailed Description
-----------------
Insulin is a hormone produced by the body that lets sugar into the cells, where it is used for energy. Insulin resistance occurs when the body's cells have a decreased ability to react to insulin. This leads to an increase in insulin secretion. Over time, insulin resistance can lead to higher levels of sugar in the blood (diabetes), and can also contribute to obesity, high blood pressure, high cholesterol levels and heart disease. There are no simple tests to actually diagnose insulin resistance. Currently, the glucose tolerance test is used to diagnose IR, but it involves several blood draws over a 2-hour period. Another purpose of this study is to compare a blood test involving only one blood draw to the 2-hour glucose tolerance test, which involves several blood draws over a 2-hour period. It is well known that diabetes often leads to erectile dysfunction. Because insulin resistance occurs before diabetes, it is possible that erectile dysfunction may occur in some individuals while they have insulin resistance, but before they develop diabetes. If this is true, it might be possible to use erectile dysfunction as a sign of insulin resistance, which may lead to more timely treatment of insulin resistance and may delay or prevent the development of diabetes, and the other problems mentioned above.

Official Title
-----------------
The Incidence and Treatment of Insulin Resistance Among Men With Erectile Dysfunction

Conditions
-----------------
Erectile Dysfunction, Metabolic Syndrome, Insulin Resistance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-65 years of age, male, Exclusion Criteria: diabetes, peyronies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
erectile dysfunction, metabolic syndrome, insulin resistance, etiology
Impact of Hydroxocobalamine on Outcome of Smoke Inhalation Injury Admitted to the ICU

Study Overview
=================
Brief Summary
-----------------
In Europe, hydroxocobalamin (cyanokit) has been used for suspicion of cyanide intoxication associated with the inhalation of fire smoke (1). However, the impact of hydroxocobalamin on outcome has never been thoroughly evaluated. While hydroxocobalamin has long been presented as being side-effect free, recent data suggest that in patients with severe burns, its use was associated with the occurrence of acute renal failure by intra tubular precipitation of oxalate crystals (2, 3). The purpose of this observational study is to investigate the association between use of hydroxocobalamin and outcome after smoke inhalation.

Detailed Description
-----------------
In Europe, hydroxocobalamin (cyanokit) is the antidote recommended by expert consensus in cases of suspicion of cyanide intoxication associated with the inhalation of fire smoke (1). However, cyanokit has never been evaluated in this indication. Clinical data suggest that in patients with severe burns, its use is associated with the occurrence of acute kidney injury by intra tubular precipitation of oxalate crystals (2, 3). The purpose of this observational study is to investigate the association between use of hydroxocobalamin and outcome after smoke inhalation. The results of this study should guide future research and advice on the benefit-risk ratio of hydroxocobalamin.

Official Title
-----------------
Impact of Hydroxocobalamine on Outcome of Smoke Inhalation Injury Admitted to the ICU

Conditions
-----------------
Smoke Inhalation Patients

Intervention / Treatment
-----------------
* Other: There is no intervention planned (observational)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admission in ICU with smoke inhalation diagnosed Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: There is no intervention planned (observational)|There is no intervention planned (observational)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| in ICU mortality | mortality in ICU or at day 90 | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| in ICU acute kidney injury (based on the KDIGO definition) | AKI in ICU or at day 90 | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Smoke inhalation injury, Acute kidney injury, Intensive care unit, Burns, Prognosis, Hydroxocobalamin
Genetics of Ankylosing Spondylitis

Study Overview
=================
Brief Summary
-----------------
Ankylosing spondylitis (AS) is a chronic inflammatory disease that affects the joints between the vertebrae of the spine and the joints between the spine and the pelvis. The purpose of this study is to collect information and blood samples from patients with AS and their relatives for use in genetic studies.

Detailed Description
-----------------
AS is a chronic inflammatory disease that eventually causes the affected vertebrae to fuse or grow together. The cause of AS is unknown, but genetic factors seem to play a role. Risk factors include a family history of ankylosing spondylitis and male gender. This study will collect patient information and blood samples from affected patients (and when available, both parents of the affected patients) of 400 families with children fulfillling the modified New York criteria for AS. Diagnosis of AS will be verified by patient questionnaire, medical record review, and pelvic radiographs. Information from these patients will be used to search the human genome for disease-associated loci and/or genes. This study will also utilize contributions of investigators who have conducted recent clinical or genetic research in AS at 10 academic medical centers throughout North America (the North American Spondylitis Consortium, or NASC).

Official Title
-----------------
Family Studies of the Genetics of Ankylosing Spondylitis

Conditions
-----------------
Spondylitis, Ankylosing Spondylitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meet modified New York criteria for ankylosing spondylitis (AS) AS as confirmed by X-rays of sacroiliac joints (between the pelvis and spine) At least two siblings in family with AS Parents of the participants with AS have the option of also being enrolled
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus Disease

Study Overview
=================
Brief Summary
-----------------
This study highlighted the possibility, even in epidemic settings, of providing advanced supportive care for patients with VMEs. Indeed, while the prospect of offering any invasive medical care was widely discussed in 2014 in West Africa with the aim of limiting the exposure of caregivers, the epidemic of 2018-2019 has on the contrary seen the development of a number of medical care strategies, in parallel with the deployment of specific treatments. This study aims to describe a cohort of patients receiving this upgraded supportive care during the tenth epidemic in the DRC.

Official Title
-----------------
Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus Disease

Conditions
-----------------
Ebola Virus Disease

Intervention / Treatment
-----------------
* Other: Standard of Care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Laboratory confirmed Ebola Virus Disease Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Standard of Care|(i) advanced clinical and biological monitoring system (ii) symptomatic treatment adapted to the patient's needs, such as antibiotic therapy, oxygen therapy and blood transfusion; (iii) dialysis or mechanical ventilation.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Any type mortality during hospitalization | Through the end of the hospitalization, with an average of 11 days |
The Application of Spasmolytic in PCLE Examination of Superior Gastrointestinal Endoscope

Study Overview
=================
Brief Summary
-----------------
Scopolamine butylbromide might be helpful for the outcome of superior gastrointestinal endoscope examination.

Detailed Description
-----------------
The peristalsis of gastrointestinal tract has a adverse affection on the process of the PCLE examination .Scopolamine butylbromide is a widely used spasmolytic，which can reduce the peristalsis of gastrointestinal tract effectly.The application of it may benefit the images'quality ,the acurrate of diagnosis and shorten the examination time.

Official Title
-----------------
A Clinical Analysis of Scopolamine Hydrobromide in Probe-based Confocal Laser Endomicroscopy for Gastroendoscopy Examination

Conditions
-----------------
Using Copolamine Butylbromide in Probe-based Confocal Laser Endomicroscopy for Gastroendoscopy Examination

Intervention / Treatment
-----------------
* Drug: Scopolamine Hydrobromide
* Drug: normal saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: outpatients attending endomicroscopy able to give written informed consent Exclusion Criteria: coagulopathy acute upper digestive tract bleeding pregnancy or breast feeding allergy to fluorescein sodium impaired renal function

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: A group<br>Using normal saline before pcle examination | Drug: normal saline<br> <br> |
| Experimental: B group<br>Using Scopolamine Hydrobromide before pcle examination | Drug: Scopolamine Hydrobromide<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endomicroscopic image quality |  | 7months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Scopolamine butylbromide PCLE
Mitral Valve Area Assessment: Comparison With Transthoracic Echocardiography and Magnetic Resonance Imaging

Study Overview
=================
Brief Summary
-----------------
To compare mitral valve area in rheumatic mitral valve stenosis with cardiac magnetic resonance imaging and conventional transthoracic echocardiography.

Detailed Description
-----------------
Clinical assessment of severity of mitral stenosis depends on both the presence of symptoms and mitral valve area . Evaluation of mitral valve area with transthoracic echocardiography maintains rapid, accurate analysis of valve disease and serves as a practical gold standard for clinical evaluation. Cardiac magnetic resonance imaging (CMRI) is a recently used method that allows to evaluate cardiac structures and function noninvasively. Direct visualization of valve area with CMRI is also possible and it has been shown that the valve area assessed by CMRI planimetry correlates reliably with the invasive assessment. Velocity-encoded cardiac magnetic resonance imaging can be used to quantify mitral valve area. The objective of this study was to evaluate mitral valve area with CMRI and compare it with echocardiographic methods including 2D planimetry, Doppler continuation equation and Doppler pressure half-time

Official Title
-----------------
Quantification of Rheumatic Mitral Stenosis With Cardiac Magnetic Resonance Imaging and Comparison With Transthoracic Echocardiography

Conditions
-----------------
Mitral Valve Stenosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: rheumatic mitral valve stenosis Exclusion Criteria: Degenerative mitral valve disease EF<50% atrial fibrillation inconclusive planimetric assessment moderate or severe mitral regurgitation moderate or severe aortic regurgitation history of previous mitral valve commissurotomy or balloon valvotomy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>Mitral valve area above 1.5 cm2 | |
| B<br>Mitral valve area 1.5 cm2 and below 1.5 cm2 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
magnetic resonance imaging, mitral valve area
Diagnosis of Pulmonary Embolism by Doppler Signals

Study Overview
=================
Brief Summary
-----------------
The LDS may contain information of significant diagnostic and physiological value regarding the pulmonary parenchyma and vasculature, as well as the cardio- vascular system in general. In pilot clinical studies of patients with acute decompensated heart failure (ADHF) as well as patients with Pulmonary Hypertension, LDS signals patterns unique to these conditions were identified. We believe that these newly discovered ultrasound signals might provide a non-invasive radiation-free means to diagnose and monitor patients with Pulmonary Embolism. The purpose of this study is to assess the utility of noninvasive assessment of lung Doppler signals performed via transthoracic parametric Doppler. The objective of the study is to evaluate the lung Doppler signals (LDS) in patients diagnosed with acute PE, in order to determine the potential assessment value of this non-invasive method in this potentially life threatening condition.

Official Title
-----------------
Transthoracic Parametric Doppler Assessment of Lung Doppler Signals in Acute Pulmonary Embolism

Conditions
-----------------
Pulmonary Embolism

Intervention / Treatment
-----------------
* Radiation: Diagnostic ultrasound radiation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of acute PE on CTA Exclusion Criteria: Pregnant women Inability to consent Patients with severe chest wall deformity Previously diagnosed PE Pneumonia Pulmonary edema Pneumothorax Severe COPD (gold class III, IV) Hemodynamically unstable patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Diagnostic ultrasound<br>Recording Doppler ultrasound signals noninvasively from the right chest wall | Radiation: Diagnostic ultrasound radiation<br>* Recording Doppler ultrasound signals from the right chest wall<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify lack of Lung Doppler signals in specific lung sections that were diagnosed obstructed by CT | The obstructed sections will be compared with healthy lung sections | 30min | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pulmonary embolism, pulmonary disease, Lung Doppler signals
Discrepancies Between Patients and Physicians in Their Perceptions of Rheumatoid Arthritis Disease Activity

Study Overview
=================
Brief Summary
-----------------
Patients and physicians often differ in their perceptions of rheumatoid arthritis (RA) disease activity, as quantified by the patient's global assessment (PGA) and by the evaluator's global assessment (EGA). The objectives of this study were: to explore the extent and reasons for the discordance between patients and physicians in their perception of RA disease activity to determine if this discordance at baseline is associated with RA outcomes at 1 year (remission, function and structure) in early arthritis (EA) in daily clinical practice. Patients: from the French cohort of early arthritis (EA) ESPOIR³ (at least 2 swollen joints for less than 6 months, DMARD naïve), fulfilling the ACR-EULAR criteria for RA at baseline Analysis: At baseline, agreement between PGA and EGA (Bland-Altman plot) was assessed. Multivariate linear regression was used to determine the patient and EA features independently associated with discordance (calculated as PGA - EGA). Logistic regression was used to analyze discordance as│PGA - EGA│≥20. Multivariate logistic models were used to determine if discordance at baseline is associated with remissions (Boolean, SDAI and DAS28), functional stability (HAQ≤0.5 and deltaHAQ≤0.25) and absence of radiographic progression (delta Sharp score<1) after 1 year of follow-up.

Official Title
-----------------
Discordance Dans l'évaluation d'Activité de la Polyarthrite Rhumatoide

Conditions
-----------------
Rheumatoid Arthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: fulfilling the ACR-EULAR criteria for RA Exclusion Criteria: no RA

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 110 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient's global assessment | The discordance between the patient's and the evaluator's global assessment will be calculated. | day 0 | 
| Evaluator's global assessment | The discordance between the patient's and the evaluator's global assessment will be calculated. | day 0 |
The Vancouver-BOLD Study: The Burden of Chronic Obstructive Lung Disease

Study Overview
=================
Brief Summary
-----------------
This is a study of the lung health of the population of Vancouver and the extent of, and the risk factors for, chronic obstructive lung disease.

Official Title
-----------------
The Burden of Chronic Obstructive Lung Disease (BOLD) Study

Conditions
-----------------
Chronic Obstructive Lung Disease

Intervention / Treatment
-----------------
* Behavioral: Study to determine the burden of disease


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 40 years of age and older Both sexes Random sample of population Exclusion Criteria: Contraindication for lung function testing and serious life threatening illness.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Study to determine the burden of disease|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung health | Lung health of the population of Vancouver and the extent of, and the risk factors for, chronic obstructive lung disease | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Epidemiology, Lung health, lung function, COPD
Effect of EGDT on Hepatic Perfusion in Patients With Septic Shock

Study Overview
=================
Brief Summary
-----------------
To observe the effect of early goal directed therapy (EGDT) on hepatic perfusion in patients with septic shock. Hypothesis: Hepatic perfusion did not improved after EGDT in patients with septic shock.

Detailed Description
-----------------
Objective To observe the effect of early goal directed therapy (EGDT) on hepatic perfusion in patients with septic shock. Methods A prospective observational study was carried out. The eligible patients were treated with the standard procedure of EGDT. The hemodynamic data were recorded. Oxygen metabolism and hepatic function were monitored. Indocyanine clearance test was applied to detect the hepatic perfusion. Hemodynamics, hepatic perfusion, oxygen metabolism and hepatic function were compared before treatment, after EGDT and 24 hours after EGDT.

Official Title
-----------------
Effect of EGDT on Hepatic Perfusion in Patients With Septic Shock

Conditions
-----------------
Septic Shock

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with septic shock at least one of the EGDT criteria not achieved informed consent accepted Exclusion Criteria: ages below 18 or above 90 pregnancy the time elapsed over 24 hours after onset of septic shock chronic liver disease terminal stage of disease brain death other types of shock brain injury allergic to iodine or indocyanine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ICG-PDR and R15 before treatment, after EGDT and 24 hours after EGDT. |  | 30 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 28 days mortality | Follow up to determine the mortality in 28 days after inclusion | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Septic shock, Early goal directed therapy, Fluid resuscitation, Hepatic perfusion, Indocyanine Green